Zobrazeno 1 - 10
of 300
pro vyhledávání: '"Anthony V Moorman"'
Autor:
Nadine Farah, Amy A Kirkwood, Sunniyat Rahman, Theresa Leon, Sarah Jenkinson, Rosemary E. Gale, Katharine Patrick, Jeremy Hancock, Sujith Samarasinghe, David C. Linch, Anthony V Moorman, Nicholas Goulden, Ajay Vora, Marc R. Mansour
Publikováno v:
Haematologica, Vol 103, Iss 7 (2018)
Externí odkaz:
https://doaj.org/article/2fd597fa6b7a4851a807edf8f7f8b49a
Autor:
Ashish Narayan Masurekar, Catriona A Parker, Milensu Shanyinde, Anthony V Moorman, Jeremy P Hancock, Rosemary Sutton, Philip J Ancliff, Mary Morgan, Nicholas J Goulden, Chris Fraser, Peter M Hoogerbrugge, Tamas Revesz, Philip J Darbyshire, Shekhar Krishnan, Sharon B Love, Vaskar Saha
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e108107 (2014)
The outcomes of Central Nervous System (CNS) relapses in children with acute lymphoblastic leukaemia (ALL) treated in the ALL R3 trial, between January 2003 and March 2011 were analysed. Patients were risk stratified, to receive a matched donor allog
Externí odkaz:
https://doaj.org/article/a33a747b941a4d608fce934190131089
Autor:
Hayden L. Bell, Helen J. Blair, Mankaran Singh, Anthony V. Moorman, Olaf Heidenreich, Frederik W. van Delft, John Lunec, Julie A. E. Irving
Publikováno v:
Cancer Cell International, Vol 23, Iss 1, Pp 1-14 (2023)
Abstract Background Outcomes for patients with relapsed acute lymphoblastic leukemia (ALL) are poor and there is a need for novel therapies to improve outcomes. Targeted inhibition of WEE1 with small-molecule inhibitor adavosertib (AZD1775) has emerg
Externí odkaz:
https://doaj.org/article/9deed2b8e0db4595931334af42559dac
Autor:
Anna Østergaard, Amir Enshaei, Rob Pieters, Ajay Vora, Martin A. Horstmann, Gabriele Escherich, Bertil Johansson, Mats Heyman, Kjeld Schmiegelow, Peter M. Hoogerbrugge, Monique L. den Boer, Roland P. Kuiper, Anthony V. Moorman, Judith M. Boer, Frank N. van Leeuwen
Publikováno v:
HemaSphere, Vol 7, Iss 5, p e875 (2023)
IKZF1 deletions are an established prognostic factor in childhood acute lymphoblastic leukemia (ALL). However, their relevance in patients with good risk genetics, namely ETV6::RUNX1 and high hyperdiploid (HeH), ALL remains unclear. We assessed the p
Externí odkaz:
https://doaj.org/article/5645c5c18f97430d84ab7aaaba94a6bf
Autor:
Sanjeev Kumar Gupta, Minu Singh, Pragna H. Chandrashekar, Sameer Bakhshi, Amita Trehan, Ritu Gupta, Rozy Thakur, Smeeta Gajendra, Preity Sharma, Sreejesh Sreedharanunni, Manupdesh S. Sachdeva, Deepam Pushpam, Neelam Varma, Deepak Bansal, Richa Jain, Srinivasan Peyam, Anthony V. Moorman, Prateek Bhatia
Publikováno v:
HemaSphere, Vol 6, Iss 10, p e782 (2022)
Copy number alteration (CNA) status and CNA risk profiles of IKZF1plus, UK-ALL CNA risk groups and MRplus scores, were evaluated for clinical and prognostic impact in a cohort of 493 B-cell acute lymphoblastic leukemia cases diagnosed and treated und
Externí odkaz:
https://doaj.org/article/b950bc5a01cc428cb83e1fab0526250c
Autor:
Simon Bomken, Amir Enshaei, Edward C. Schwalbe, Aneta Mikulasova, Yunfeng Dai, Masood Zaka, Kent T.M. Fung, Matthew Bashton, Huezin Lim, Lisa Jones, Nefeli Karataraki, Emily Winterman, Cody Ashby, Andishe Attarbaschi, Yves Bertrand, Jutta Bradtke, Barbara Buldini, G.A. Amos Burke, Giovanni Cazzaniga, Gudrun Gohring, Hesta A. De Groot-Kruseman, Claudia Haferlach, Luca Lo Nigro, Mayur Parihar, Adriana Plesa, Emma Seaford, Edwin Sonneveld, Sabine Strehl, Vincent H.J. Van der Velden, Vikki Rand, Stephen P. Hunger, Christine J. Harrison, Chris M. Bacon, Frederik W. Van Delft, Mignon L. Loh, John Moppett, Josef Vormoor, Brian A. Walker, Anthony V. Moorman, Lisa J. Russell
Publikováno v:
Haematologica, 108(3), 717-731. Ferrata Storti Foundation
Rarely, immunophenotypically immature B-cell precursor acute lymphoblastic leukemia (BCP-ALL) carries an immunoglobulin- MYC rearrangement (IG-MYC-r). This can result in diagnostic confusion with Burkitt lymphoma/leukemia and use of individualized tr
Autor:
Paul B. Sinclair, Ruth E. Cranston, Prahlad Raninga, Joanna Cheng, Rebecca Hanna, Zoe Hawking, Steven Hair, Sarra L. Ryan, Amir Enshaei, Sirintra Nakjang, Vikki Rand, Helen J. Blair, Anthony V. Moorman, Olaf Heidenreich, Christine J. Harrison
Publikováno v:
Leukemia. 37:636-649
A common problem in the study of human malignancy is the elucidation of cancer driver mechanisms associated with recurrent deletion of regions containing multiple genes. Taking B-cell acute lymphoblastic leukaemia (B-ALL) and large deletions of 6q [d
Autor:
Sarra L. Ryan, John F. Peden, Zoya Kingsbury, Claire J. Schwab, Terena James, Petri Polonen, Martina Mijuskovic, Jenn Becq, Richard Yim, Ruth E. Cranston, Dale J. Hedges, Kathryn G. Roberts, Charles G. Mullighan, Ajay Vora, Lisa J. Russell, Robert Bain, Anthony V. Moorman, David R. Bentley, Christine J. Harrison, Mark T. Ross
Publikováno v:
Leukemia. 37:518-528
Childhood B-cell acute lymphoblastic leukaemia (B-ALL) is characterised by recurrent genetic abnormalities that drive risk-directed treatment strategies. Using current techniques, accurate detection of such aberrations can be challenging, due to the
Autor:
Claire Schwab, Ruth E. Cranston, Sarra L. Ryan, Ellie Butler, Emily Winterman, Zoe Hawking, Matthew Bashton, Amir Enshaei, Lisa J. Russell, Zoya Kingsbury, John F. Peden, Emilio Barretta, James Murray, Jude Gibson, Andrew C. Hinchliffe, Robert Bain, Ajay Vora, David R. Bentley, Mark T. Ross, Anthony V. Moorman, Christine J. Harrison
Publikováno v:
Leukemia. 37:529-538
Incorporating genetics into risk-stratification for treatment of childhood B-progenitor acute lymphoblastic leukaemia (B-ALL) has contributed significantly to improved survival. In about 30% B-ALL (B-other-ALL) without well-established chromosomal ch
Autor:
Anthony V. Moorman, Grace Antony, Rachel Wade, Ellie R. Butler, Amir Enshaei, Christine J. Harrison, John Moppett, Rachael Hough, Clare Rowntree, Jeremy Hancock, Nicholas Goulden, Sujith Samarasinghe, Ajay Vora
Publikováno v:
Journal of Clinical Oncology. 40:4228-4239
PURPOSE The aim of the randomized trial, UKALL2003, was to adjust treatment intensity on the basis of minimal residual disease (MRD) stratification for children and young adults with acute lymphoblastic leukemia. We analyzed the 10-year randomized ou